[1]
|
H. HogenEsch, “Mechanisms of Stimulation of the Immune Response by Aluminum Adjuvants,” Vaccine, Vol. 20, Suppl. 3, 2002, pp. 34-39.
doi:10.1016/S0264-410X(02)00169-X
|
[2]
|
M. Kool , T. Soullié ,M. Van Nimwegen, M.A. Willart, F. Muskens, S. Jung, H.C. Hoogsteden, H. Hammad and B. Lambrecht, “Alum Adjuvants Boosts Adaptive Immunity by Inducing Uric Acid and Activating Inflammatory Dendritic Cells,” The Journal of Experimental Medicine, Vol. 205, No. 4, 2008, pp. 869-882.
doi:10.1084/jem.20071087
|
[3]
|
E. B. Lindblad, “Aluminum Adjuvants in Retrospect and Prospect,” Vaccine, Vol. 13, No. 22, 2004, pp. 3658-3668.
doi:10.1016/j.vaccine.2004.03.032
|
[4]
|
E. DeGregorio, E. Tritto and R. Rappuoli, “Alum Adjuvanticity: Unraveling a Century Old Mystery,” European Journal of Immunology, Vol. 38, No. 8, 2008 pp. 2068- 2071. doi:10.1002/eji.200838648
|
[5]
|
J. N. Francis and S. R. Durham, “Adjuvants for Allergen Immunotherapy: Experimental Results and Clinical Perspectives,” Current Opinion in Allergy and Clinical Immunology, Vol. 4, No. 6, 2004, pp. 543-548.
doi:10.1097/00130832-200412000-00012
|
[6]
|
M. B. Jordan, D. M. Mills, J. Kappler, P. Marrack and J. C. Cambier, “Promotion of B Cell Immune Responses via an Alum-Induced Myeloid Cell Population,” Science, Vol. 304, No. 5678, 2004, pp. 1808-1810.
doi:10.1126/science.1089926
|
[7]
|
H. Li, S. Nookala and F. Re, “Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1 Beta and IL-18 Release,” Journal of Immunology, Vol. 178, No. 8, 2001, pp. 5271-5276.
|
[8]
|
J. C. Cox and A. R. Coulter, “Adjuvants—A Classification and Review of Their Modes of Action,” Vaccine, Vol. 15, No. 3, 1997, pp. 248-256.
doi:10.1016/S0264-410X(96)00183-1
|
[9]
|
M. Ulanova, A. Tarkowski, M. Hahn-Zoric and L. Hanson, “The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory Properties of Human Monocytes via an Interleukin-4-Dependent Mechanism,” Infection and Immunity, Vol. 69, No. 2, 2001, pp. 1151- 1159. doi:10.1128/IAI.69.2.1151-1159.2001
|
[10]
|
R. G. White, A. H. Coons and J. M. Connoly, “Studies on Antibody Production. III. The Alum Granuloma,” Journal of Experimental Medicine, Vol. 102, No. 1, 1955, pp. 73- 82. doi:10.1084/jem.102.1.73
|
[11]
|
G. L. Morefield, A. Sokolovska, D. Jiang, H. HegenESch, J. P. Robison and S. L. Hem, “Role of Aluminum-Con- taining Adjuvants in Antigen Internalization by Dendritic Cells in Vitro,” Vaccine, Vol. 23, No. 13, 2005, pp. 1588- 1595. doi:10.1016/j.vaccine.2004.07.050
|
[12]
|
E. Tritto, F. Mosca and E. De Gregorio, “Mechanism of Action of Licensed Vaccine Adjuvants,” Vaccine, Vol. 27, No. 25-26, 2009, pp. 3331-3334.
doi:10.1016/j.vaccine.2009.01.084
|
[13]
|
S. Galluci, M. Lolkema and P. Matzinger, “Natural Adjuvants: Endogenous Activators of Dendritic Cells,” Nature Medicine, Vol. 5, No. 11, 2000, pp. 1249-1255.
doi:10.1038/15200
|
[14]
|
D. E. Hu, A. Moore, L. Thomsen and K. Brindle, “Uric Acid Promotes Tumor Immune Rejection,” Cancer Research, Vol. 64, No. 15, 2004, pp. 5059-5062.
doi:10.1158/0008-5472.CAN-04-1586
|
[15]
|
Y. Shi, J. E. Evans and K. L. Rock, “Molecular Identification of a Danger Signal That Alerts the Immune System to Dying Cells,” Nature, Vol. 425, No. 6957, 2003, pp. 516-521. doi:10.1038/nature01991
|
[16]
|
M. Behrens, W. Wagner, C. Krco, C. Erskine, K. Kalli , J. Krempski, E. Gad, M. Disis and K. Knutson, “The Endogenous Danger Signal, Crystalline Uric Acid, Signals for Enhanced Antibody Immunity,” Blood, Vol. 111, No. 3, 2008, pp. 1472-1479.
doi:10.1182/blood-2007-10-117184
|
[17]
|
R. L. Hunter, “Overview of Vaccine Adjuvants: Present and Future,” Vaccine, Vol. 20, No. 3, 2002, pp. 7-12.
doi:10.1016/S0264-410X(02)00164-0
|
[18]
|
F. Martinon, V. Petrilli, A. Mayor, A. Tardivel and J. Tschopp, “Gout Associated Uric Acid Crystals Activate the NALP3 Inflammasome,” Nature, Vol. 440, No. 7081, 2006, pp. 237-241. doi:10.1038/nature04516
|
[19]
|
Y. Shi, W. Zheng and K. L. Rock, “Cell Injury Releases Endogenous Adjuvants That Stimulate Cytotoxic T Cell Responses,” Proceedings of the National Academy of Science, Vol. 97, No. 26, 2000, pp. 14590-14595.
doi:10.1073/pnas.260497597
|
[20]
|
Y. Shi, S. A. Galusha and K. L. Rock, “Cutting Edge: Elimination of an Endogenous Adjuvant Reduces the Activation of CD8 T Lymphocytes to Transplanted Cells and in an Autoimmune Diabetes Model,” Journal of Immunology, Vol. 176, No. 7, 2006, pp. 3905-3908.
|
[21]
|
R. Webb, M. Jeffries and A. H. Sawalha, “Uric Acid Directly Promotes Human T-Cell Activation,” The American Journal of the Medical Sciences, Vol. 337, No. 1, 2009, pp. 23-27. doi:10.1097/MAJ.0b013e31817727af
|
[22]
|
G. Vielhauer, E. Gad, W. Wagner, M. L. Disis and K. L. Knutson, “The Endogenous Danger Signaling Molecule, Uric Acid, Converts Immunity from Non-Protective to Protective When Used as a Vaccine Adjuvant,” American Association for Cancer Research, Vol. 46, 2005, Abstract 5167.
|
[23]
|
J. M. Brewer, M. Conacher, A. Satoskar, H. Bluethmann and J. Alexander, “In Interleukin-4 Deficient Mice, Alum Not Only Generates T Helper-1 Responses Equivalent to Freund’s Complete Adjuvant, But Continues to Induce T Helper-2 Cytokine Production,” Journal of Immunology, Vol. 26, No. 9, 1996, pp. 2062-2066.
|
[24]
|
W. S. Waring, J. D. Webb and R. J. S. Maxwell, “Systemic Uric Acid Administration Increases Serum Antioxidant Capacity in Healthy Volunteers,” Journal of Cardiovascular Pharmacology, Vol. 38, No. 3, 2001, pp. 365-371. doi:10.1097/00005344-200109000-00005
|
[25]
|
G. B. Elion, “The Purine Path to Chemotherapy,” Bioscience Reports, Vol. 9, No. 5, 1989, pp. 509-529.
doi:10.1007/BF01119794
|
[26]
|
G. B. Elion, “Enzymatic and Metabolic Studies with Allopurinol,” Annals of the Rheumatic Diseases, Vol. 25, No. 6, 1966, pp. 608-614.
|
[27]
|
J. R. Parratt, “Nitric Oxide in Sepsis and Endotoxaemia,” Journal of Antimicrobial Chemotherapy, Vol. 41, Suppl. A, 1998, pp. 31-39. doi:10.1093/jac/41.suppl_1.31
|